Evidence map›Paper›PMID 41929084›Full record

ArticlebioRxiv : the preprint server for biology2026

OPTIMIS: Optimizing Personalized Therapies through Integrated Multiscale Intelligent Simulation.

Zhaoqian Su, Yinghao Wu

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhaoqian SuResearch, Takeda Pharmaceutical Company Ltd., Cambridge, 02139, MA, USA.
Yinghao WuDepartment of Systems and Computational Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461.ORCID 0000-0003-1181-5670

Funding

Computational models for the signaling of tumor necrosis factor receptor on cell surfacesR01GM122804 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WU, YINGHAO · 2017 to 2020
$1.3M
NIGMS NIH HHS R01 GM122804
6 · The paper itself

Abstract

Controlling complex biological systems across multiple scales remains a major challenge in computational medicine, because whole-body disease behavior is closely shaped by noisy cellular events at much smaller scales. Standard deterministic models often miss this molecular variability, while fully stochastic simulations are too slow for the repeated, high-throughput interactions needed to train artificial intelligence. To address this problem, we developed a new AI-based framework that combines a discrete stochastic Gillespie algorithm for microscale receptor dynamics with continuous, nonlinear ordinary differential equations for systemic macroscale behavior. To reach the speed needed for deep reinforcement learning (RL), we compress this hybrid system into a differentiable Neural ODE surrogate that acts as a fast digital twin. As a proof of concept, we applied this framework to engineered cellular therapy and used RL agents to learn dynamic, closed-loop treatment policies inside the surrogate environment. By tracking microscopic, unpredictable cellular activity as an early-warning signal, the AI learned to continuously adjust the drug dose-anticipating and stopping dangerous immune reactions before they could spiral out of control. This computational advance improved successful control rates to more than 70% in highly unstable simulated phenotypes and provides a practical, general framework for adaptive intervention in multiscale biological systems.

Identifiers

PMID41929084
PMCPMC13041881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.